10-Q Filing

IOVANCE BIOTHERAPEUTICS, INC. CIK: 1425205 Q3 2012

Filing Information

Form Type	10-Q
Accession Number	`0001513160-13-000022`
Period End Date	20120930
Filing Date	20130125
Fiscal Year	2012
Fiscal Period	Q3
XBRL Instance	gnpb-20120930.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 50 Income Statement 73 Cash Flow Statement 105 Stockholders Equity 13

Balance Sheet 50 line items

Line Item	Tag	Value	Unit	Period
Cash and cash equivalents	`Cash`	$510.22K	USD	Point-in-time
Property and equipment, accumulated depreciation	`AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment`	$2.70K	USD	Point-in-time
Property and equipment, accumulated depreciation	`AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment`	$7.36K	USD	Point-in-time
Cash and cash equivalents	`Cash`	-	USD	Point-in-time
Deposits and prepaid expenses	`PrepaidExpenseAndOtherAssetsCurrent`	$5.00K	USD	Point-in-time
Deposits and prepaid expenses	`PrepaidExpenseAndOtherAssetsCurrent`	$13.86K	USD	Point-in-time
Common Stock Par Value	`CommonStockParOrStatedValuePerShare`	-	USD	Point-in-time
Common Stock Par Value	`CommonStockParOrStatedValuePerShare`	-	USD	Point-in-time
Total current assets	`AssetsCurrent`	$524.08K	USD	Point-in-time
Total current assets	`AssetsCurrent`	$5.00K	USD	Point-in-time
Property and equipment, net of accumulated depreciation of $5,361 and $2,704	`PropertyPlantAndEquipmentNet`	$23.69K	USD	Point-in-time
Common Stock Shares Authorized	`CommonStockSharesAuthorized`	1.80B	shares	Point-in-time
Property and equipment, net of accumulated depreciation of $5,361 and $2,704	`PropertyPlantAndEquipmentNet`	$28.35K	USD	Point-in-time
Common Stock Shares Authorized	`CommonStockSharesAuthorized`	1.80B	shares	Point-in-time
Common Stock Shares Issued	`CommonStockSharesIssued`	78.29M	shares	Point-in-time
Rent Deposit	`DepositsAssetsNoncurrent`	-	USD	Point-in-time
Common Stock Shares Issued	`CommonStockSharesIssued`	77.99M	shares	Point-in-time
Rent Deposit	`DepositsAssetsNoncurrent`	$16.00K	USD	Point-in-time
Total assets	`Assets`	$568.43K	USD	Point-in-time
Total assets	`Assets`	$28.69K	USD	Point-in-time
Common Stock Shares Outstanding	`CommonStockSharesOutstanding`	78.29M	shares	Point-in-time
Common Stock Shares Outstanding	`CommonStockSharesOutstanding`	77.99M	shares	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$841.62K	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$190.05K	USD	Point-in-time
Accrued expenses	`InterestPayableCurrent`	$221.51K	USD	Point-in-time
Accrued expenses	`InterestPayableCurrent`	$1.01M	USD	Point-in-time
Accrued expenses - National Institutes of Health	`OtherAccruedLiabilitiesCurrent`	$616.00K	USD	Point-in-time
Accrued expenses - National Institutes of Health	`OtherAccruedLiabilitiesCurrent`	-	USD	Point-in-time
7% convertible promissory notes	`ConvertibleNotesPayableCurrent`	$5.00M	USD	Point-in-time
7% convertible promissory notes	`ConvertibleNotesPayableCurrent`	$5.00M	USD	Point-in-time
12% secured promissory notes	`SecuredPromissoryNotes`	-	USD	Point-in-time
12% secured promissory notes	`SecuredPromissoryNotes`	$1.23M	USD	Point-in-time
September 2012 secured promissory note	`SecuredDebtCurrent`	$250.00K	USD	Point-in-time
September 2012 secured promissory note	`SecuredDebtCurrent`	-	USD	Point-in-time
Derivative liabilities	`DerivativeLiabilitiesCurrent`	$7.66M	USD	Point-in-time
Derivative liabilities	`DerivativeLiabilitiesCurrent`	$7.94M	USD	Point-in-time
Total Current Liabilities	`LiabilitiesCurrent`	$16.61M	USD	Point-in-time
Total Current Liabilities	`LiabilitiesCurrent`	$13.35M	USD	Point-in-time
Common stock, $0.000041666 par value; 1,800,000,000 shares authorized, 78,293,095 and 77,993,591 shares issued and outstanding, respectively	`CommonStockValue`	$3.26K	USD	Point-in-time
Common stock, $0.000041666 par value; 1,800,000,000 shares authorized, 78,293,095 and 77,993,591 shares issued and outstanding, respectively	`CommonStockValue`	$3.25K	USD	Point-in-time
Common shares to be issued	`CommonSharesToBeIssuedWith12SecuredPromissoryNotes`	$497.89K	USD	Point-in-time
Common shares to be issued	`CommonSharesToBeIssuedWith12SecuredPromissoryNotes`	-	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapitalCommonStock`	$17.07M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapitalCommonStock`	$14.59M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-34.15M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-27.38M	USD	Point-in-time
Total Stockholders' Deficiency	`StockholdersEquity`	$-12.78M	USD	Point-in-time
Total Stockholders' Deficiency	`StockholdersEquity`	$-16.58M	USD	Point-in-time
Total Liabilities and Stockholders' Deficiency	`LiabilitiesAndStockholdersEquity`	$28.69K	USD	Point-in-time
Total Liabilities and Stockholders' Deficiency	`LiabilitiesAndStockholdersEquity`	$568.43K	USD	Point-in-time

Income Statement 73 line items

Line Item	Tag	Value	Unit	Period
Revenues	`SalesRevenueGoodsNet`	-	USD	3 Qtrs
Revenues	`SalesRevenueGoodsNet`	-	USD	1 Quarter
Revenues	`SalesRevenueGoodsNet`	-	USD	1 Quarter
Revenues	`SalesRevenueGoodsNet`	-	USD	3 Qtrs
Revenues	`SalesRevenueGoodsNet`	-	USD	20 Qtrs
Share-Based Compensation	`ShareBasedCompensation`	$697.67K	USD	1 Quarter
Share-Based Compensation	`ShareBasedCompensation`	$10.78M	USD	3 Qtrs
Share-Based Compensation	`ShareBasedCompensation`	$4.27M	USD	20 Qtrs
Share-Based Compensation	`ShareBasedCompensation`	$2.36M	USD	3 Qtrs
Share-Based Compensation	`ShareBasedCompensation`	$532.51K	USD	1 Quarter
Operating expenses (including $697,671, $532,511, $2,357,370, $10,783,000 and $4,265,240 in share-based compensation costs)	`OperatingCostsAndExpenses`	$5.81M	USD	1 Quarter
Operating expenses (including $697,671, $532,511, $2,357,370, $10,783,000 and $4,265,240 in share-based compensation costs)	`OperatingCostsAndExpenses`	$25.03M	USD	20 Qtrs
Operating expenses (including $697,671, $532,511, $2,357,370, $10,783,000 and $4,265,240 in share-based compensation costs)	`OperatingCostsAndExpenses`	$5.00M	USD	3 Qtrs
Operating expenses (including $697,671, $532,511, $2,357,370, $10,783,000 and $4,265,240 in share-based compensation costs)	`OperatingCostsAndExpenses`	$17.03M	USD	3 Qtrs
Operating expenses (including $697,671, $532,511, $2,357,370, $10,783,000 and $4,265,240 in share-based compensation costs)	`OperatingCostsAndExpenses`	$1.38M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	-	USD	3 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$250.00K	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$1.41M	USD	3 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	-	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$3.33M	USD	20 Qtrs
Impairment of intangible asset	`ImpairmentOfIntangibleAssetsExcludingGoodwill`	$160.04K	USD	20 Qtrs
Impairment of intangible asset	`ImpairmentOfIntangibleAssetsExcludingGoodwill`	-	USD	1 Quarter
Impairment of intangible asset	`ImpairmentOfIntangibleAssetsExcludingGoodwill`	-	USD	3 Qtrs
Impairment of intangible asset	`ImpairmentOfIntangibleAssetsExcludingGoodwill`	-	USD	1 Quarter
Impairment of intangible asset	`ImpairmentOfIntangibleAssetsExcludingGoodwill`	-	USD	3 Qtrs
Total costs and expenses	`OperatingExpenses`	$17.03M	USD	3 Qtrs
Total costs and expenses	`OperatingExpenses`	$5.81M	USD	1 Quarter
Total costs and expenses	`OperatingExpenses`	$1.63M	USD	1 Quarter
Total costs and expenses	`OperatingExpenses`	$28.52M	USD	20 Qtrs
Total costs and expenses	`OperatingExpenses`	$6.41M	USD	3 Qtrs
Loss from operations	`OperatingIncomeLoss`	$-17.03M	USD	3 Qtrs
Loss from operations	`OperatingIncomeLoss`	$-28.52M	USD	20 Qtrs
Loss from operations	`OperatingIncomeLoss`	$-1.63M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-5.81M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-6.41M	USD	3 Qtrs
Change in fair value of derivative liability	`IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments`	$975.70K	USD	3 Qtrs
Change in fair value of derivative liability	`IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments`	$3.24M	USD	3 Qtrs
Change in fair value of derivative liability	`IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments`	$2.34M	USD	20 Qtrs
Change in fair value of derivative liability	`IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments`	$1.60M	USD	1 Quarter
Change in fair value of derivative liability	`IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments`	$3.55M	USD	1 Quarter
Interest expense	`InterestExpense`	$31.64K	USD	3 Qtrs
Interest expense	`InterestExpense`	$31.64K	USD	1 Quarter
Interest expense	`InterestExpense`	$126.92K	USD	1 Quarter
Interest expense	`InterestExpense`	$326.56K	USD	3 Qtrs
Interest expense	`InterestExpense`	$477.71K	USD	20 Qtrs
Amortization of discount on convertible notes	`AmortizationOfDebtDiscountPremium`	-	USD	1 Quarter
Amortization of discount on convertible notes	`AmortizationOfDebtDiscountPremium`	$2.60M	USD	3 Qtrs
Amortization of discount on convertible notes	`AmortizationOfDebtDiscountPremium`	$5.50M	USD	20 Qtrs
Amortization of discount on convertible notes	`AmortizationOfDebtDiscountPremium`	$497.89K	USD	3 Qtrs
Amortization of discount on convertible notes	`AmortizationOfDebtDiscountPremium`	$2.60M	USD	1 Quarter
Private placement costs	`PrivatePlacementCosts`	$515.27K	USD	3 Qtrs
Private placement costs	`PrivatePlacementCosts`	$920.31K	USD	1 Quarter
Private placement costs	`PrivatePlacementCosts`	$515.27K	USD	1 Quarter
Private placement costs	`PrivatePlacementCosts`	$920.31K	USD	3 Qtrs
Private placement costs	`PrivatePlacementCosts`	$2.00M	USD	20 Qtrs
Total other income (expense)	`OtherNonoperatingIncomeExpense`	$-364.02K	USD	3 Qtrs
Total other income (expense)	`OtherNonoperatingIncomeExpense`	$-308.94K	USD	3 Qtrs
Total other income (expense)	`OtherNonoperatingIncomeExpense`	$-4.34K	USD	1 Quarter
Total other income (expense)	`OtherNonoperatingIncomeExpense`	$953.74K	USD	1 Quarter
Total other income (expense)	`OtherNonoperatingIncomeExpense`	$-5.63M	USD	20 Qtrs
Net Loss	`NetIncomeLoss`	$-34.15M	USD	20 Qtrs
Net Loss	`NetIncomeLoss`	$-673.90K	USD	1 Quarter
Net Loss	`NetIncomeLoss`	$-6.77M	USD	3 Qtrs
Net Loss	`NetIncomeLoss`	$-5.82M	USD	1 Quarter
Net Loss	`NetIncomeLoss`	$-17.34M	USD	3 Qtrs
Net Loss Per Share, Basic and Diluted	`EarningsPerShareBasicAndDiluted`	$-0.09	USD	3 Qtrs
Net Loss Per Share, Basic and Diluted	`EarningsPerShareBasicAndDiluted`	$-0.07	USD	1 Quarter
Net Loss Per Share, Basic and Diluted	`EarningsPerShareBasicAndDiluted`	$-0.23	USD	3 Qtrs
Net Loss Per Share, Basic and Diluted	`EarningsPerShareBasicAndDiluted`	$-0.01	USD	1 Quarter
Weighted-Average Common Shares Outstanding, Basic and Diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	78.29M	shares	1 Quarter
Weighted-Average Common Shares Outstanding, Basic and Diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	78.30M	shares	1 Quarter
Weighted-Average Common Shares Outstanding, Basic and Diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	78.24M	shares	3 Qtrs
Weighted-Average Common Shares Outstanding, Basic and Diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	74.76M	shares	3 Qtrs

Cash Flow Statement 105 line items

Line Item	Tag	Value	Unit	Period
Net loss	`NetIncomeLoss`	$-34.15M	USD	20 Qtrs
Net loss	`NetIncomeLoss`	$-673.90K	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-6.77M	USD	3 Qtrs
Net loss	`NetIncomeLoss`	$-5.82M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-17.34M	USD	3 Qtrs
Depreciation and amortization	`DepreciationAndAmortization`	$55.86K	USD	3 Qtrs
Depreciation and amortization	`DepreciationAndAmortization`	$68.73K	USD	20 Qtrs
Depreciation and amortization	`DepreciationAndAmortization`	$4.66K	USD	3 Qtrs
Impairment of intangible asset	`ImpairmentOfIntangibleAssetsExcludingGoodwill`	$160.04K	USD	20 Qtrs
Impairment of intangible asset	`ImpairmentOfIntangibleAssetsExcludingGoodwill`	-	USD	1 Quarter
Impairment of intangible asset	`ImpairmentOfIntangibleAssetsExcludingGoodwill`	-	USD	3 Qtrs
Impairment of intangible asset	`ImpairmentOfIntangibleAssetsExcludingGoodwill`	-	USD	1 Quarter
Impairment of intangible asset	`ImpairmentOfIntangibleAssetsExcludingGoodwill`	-	USD	3 Qtrs
Fair value of vested stock options and warrants	`StockOptionPlanExpense`	$532.51K	USD	3 Qtrs
Fair value of vested stock options and warrants	`StockOptionPlanExpense`	$4.27M	USD	20 Qtrs
Fair value of vested stock options and warrants	`StockOptionPlanExpense`	$2.36M	USD	3 Qtrs
Fair value of derivative liability recorded upon issuance of warrants	`FairValueOfDerivativeLiabilityRecordedUponIssuanceOfWarrants`	$2.56M	USD	3 Qtrs
Fair value of derivative liability recorded upon issuance of warrants	`FairValueOfDerivativeLiabilityRecordedUponIssuanceOfWarrants`	-	USD	3 Qtrs
Fair value of derivative liability recorded upon issuance of warrants	`FairValueOfDerivativeLiabilityRecordedUponIssuanceOfWarrants`	$2.56M	USD	20 Qtrs
Amortization of discount on notes	`AccretionAmortizationOfDiscountsAndPremiumsInvestments`	$2.60M	USD	3 Qtrs
Amortization of discount on notes	`AccretionAmortizationOfDiscountsAndPremiumsInvestments`	$5.50M	USD	20 Qtrs
Amortization of discount on notes	`AccretionAmortizationOfDiscountsAndPremiumsInvestments`	$497.89K	USD	3 Qtrs
Private placement costs	`PrivatePlacementCosts1`	$515.27K	USD	3 Qtrs
Private placement costs	`PrivatePlacementCosts1`	$920.31K	USD	3 Qtrs
Private placement costs	`PrivatePlacementCosts1`	$2.00M	USD	20 Qtrs
Change in fair value of derivative liabilities	`DerivativeGainLossOnDerivativeNet`	$3.24M	USD	3 Qtrs
Change in fair value of derivative liabilities	`DerivativeGainLossOnDerivativeNet`	$2.34M	USD	20 Qtrs
Change in fair value of derivative liabilities	`DerivativeGainLossOnDerivativeNet`	$975.70K	USD	3 Qtrs
Common stock issued to officer for services	`CommonStockIssuedToOfficerForServices`	-	USD	3 Qtrs
Common stock issued to officer for services	`CommonStockIssuedToOfficerForServices`	$8.01M	USD	20 Qtrs
Common stock issued to officer for services	`CommonStockIssuedToOfficerForServices`	$8.01M	USD	3 Qtrs
Common stock issued for services	`IssuanceOfStockAndWarrantsForServicesOrClaims`	$50.00K	USD	3 Qtrs
Common stock issued for services	`IssuanceOfStockAndWarrantsForServicesOrClaims`	$548.45K	USD	20 Qtrs
Common stock issued for services	`IssuanceOfStockAndWarrantsForServicesOrClaims`	$1.54M	USD	3 Qtrs
Fair value of common stock transferred to officer and director	`FairValueOfCommonStockTransferredToOfficerAndDirector`	$1.74M	USD	20 Qtrs
Fair value of common stock transferred to officer and director	`FairValueOfCommonStockTransferredToOfficerAndDirector`	-	USD	3 Qtrs
Fair value of common stock transferred to officer and director	`FairValueOfCommonStockTransferredToOfficerAndDirector`	$702.04K	USD	3 Qtrs
Write off of advances to related party	`WriteOffOfAdvancesToRelatedParty`	-	USD	3 Qtrs
Write off of advances to related party	`WriteOffOfAdvancesToRelatedParty`	$50.00K	USD	20 Qtrs
Write off of advances to related party	`WriteOffOfAdvancesToRelatedParty`	-	USD	3 Qtrs
Deposits, prepaid expenses and other assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$25.05K	USD	3 Qtrs
Deposits, prepaid expenses and other assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-24.86K	USD	3 Qtrs
Deposits, prepaid expenses and other assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$5.00K	USD	20 Qtrs
Accounts payable and accrued expenses	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$1.85M	USD	20 Qtrs
Accounts payable and accrued expenses	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$1.44M	USD	3 Qtrs
Accounts payable and accrued expenses	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$208.22K	USD	3 Qtrs
Accounts expenses - National Institute of Health	`IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities`	-	USD	3 Qtrs
Accounts expenses - National Institute of Health	`IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities`	$616.00K	USD	20 Qtrs
Accounts expenses - National Institute of Health	`IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities`	$616.00K	USD	3 Qtrs
Net Cash Used In Operating Activities	`NetCashProvidedByUsedInOperatingActivities`	$-3.48M	USD	3 Qtrs
Net Cash Used In Operating Activities	`NetCashProvidedByUsedInOperatingActivities`	$-2.24M	USD	3 Qtrs
Net Cash Used In Operating Activities	`NetCashProvidedByUsedInOperatingActivities`	$-9.12M	USD	20 Qtrs
Property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$20.32K	USD	3 Qtrs
Property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	-	USD	3 Qtrs
Property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$35.05K	USD	20 Qtrs
Advances to related party	`PaymentsToFundLongtermLoansToRelatedParties`	-	USD	3 Qtrs
Advances to related party	`PaymentsToFundLongtermLoansToRelatedParties`	-	USD	3 Qtrs
Advances to related party	`PaymentsToFundLongtermLoansToRelatedParties`	$50.00K	USD	20 Qtrs
Net Cash Used In Investing Activities	`NetCashProvidedByUsedInInvestingActivities`	$-20.32K	USD	3 Qtrs
Net Cash Used In Investing Activities	`NetCashProvidedByUsedInInvestingActivities`	-	USD	3 Qtrs
Net Cash Used In Investing Activities	`NetCashProvidedByUsedInInvestingActivities`	$-85.05K	USD	20 Qtrs
Proceeds from the issuance of convertible notes, net	`ProceedsFromConvertibleDebt`	$2.29M	USD	3 Qtrs
Proceeds from the issuance of convertible notes, net	`ProceedsFromConvertibleDebt`	$4.62M	USD	20 Qtrs
Proceeds from the issuance of convertible notes, net	`ProceedsFromConvertibleDebt`	-	USD	3 Qtrs
Proceeds from the issuance of secured promissory notes, net	`ProceedsFromIssuanceOfSecuredPromissoryNotesNet`	$1.48M	USD	20 Qtrs
Proceeds from the issuance of secured promissory notes, net	`ProceedsFromIssuanceOfSecuredPromissoryNotesNet`	$1.48M	USD	3 Qtrs
Proceeds from the issuance of secured promissory notes, net	`ProceedsFromIssuanceOfSecuredPromissoryNotesNet`	-	USD	3 Qtrs
Proceeds from the issuance of common stock	`ProceedsFromIssuanceOfCommonStock`	$3.09M	USD	20 Qtrs
Proceeds from the issuance of common stock	`ProceedsFromIssuanceOfCommonStock`	$873.00K	USD	3 Qtrs
Proceeds from the issuance of common stock	`ProceedsFromIssuanceOfCommonStock`	$250.00K	USD	3 Qtrs
Due to director	`IncreaseDecreaseInDueToOfficersAndStockholders`	-	USD	3 Qtrs
Due to director	`IncreaseDecreaseInDueToOfficersAndStockholders`	-	USD	3 Qtrs
Due to director	`IncreaseDecreaseInDueToOfficersAndStockholders`	$18.14K	USD	20 Qtrs
Advances to related party	`OriginationOfNotesReceivableFromRelatedParties`	-	USD	20 Qtrs
Advances to related party	`OriginationOfNotesReceivableFromRelatedParties`	$50.00K	USD	3 Qtrs
Advances to related party	`OriginationOfNotesReceivableFromRelatedParties`	-	USD	3 Qtrs
Net Cash Provided By Financing Activities	`NetCashProvidedByUsedInFinancingActivities`	$9.21M	USD	20 Qtrs
Net Cash Provided By Financing Activities	`NetCashProvidedByUsedInFinancingActivities`	$3.12M	USD	3 Qtrs
Net Cash Provided By Financing Activities	`NetCashProvidedByUsedInFinancingActivities`	$1.73M	USD	3 Qtrs
Net Decrease In Cash And Cash Equivalents	`CashAndCashEquivalentsPeriodIncreaseDecrease`	-	USD	20 Qtrs
Net Decrease In Cash And Cash Equivalents	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$-510.22K	USD	3 Qtrs
Net Decrease In Cash And Cash Equivalents	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$-381.86K	USD	3 Qtrs
Cash and Cash Equivalents, Beginning of Period	`CashAndCashEquivalentsAtCarryingValue`	$510.22K	USD	Point-in-time
Cash and Cash Equivalents, Beginning of Period	`CashAndCashEquivalentsAtCarryingValue`	$128.36K	USD	Point-in-time
Cash and Cash Equivalents, Beginning of Period	`CashAndCashEquivalentsAtCarryingValue`	-	USD	Point-in-time
Cash and Cash Equivalents, Beginning of Period	`CashAndCashEquivalentsAtCarryingValue`	$510.22K	USD	Point-in-time
Cash and Cash Equivalents, End of Period	`CashAndCashEquivalentsAtCarryingValue`	$510.22K	USD	Point-in-time
Cash and Cash Equivalents, End of Period	`CashAndCashEquivalentsAtCarryingValue`	$128.36K	USD	Point-in-time
Cash and Cash Equivalents, End of Period	`CashAndCashEquivalentsAtCarryingValue`	-	USD	Point-in-time
Cash and Cash Equivalents, End of Period	`CashAndCashEquivalentsAtCarryingValue`	$510.22K	USD	Point-in-time
Derivative liability recorded upon issuance of convertible notes and warrants	`DerivativeLiabilityRecordedUponIssuanceOfConvertibleNotesAndAttachedWarrants`	$4.62M	USD	3 Qtrs
Derivative liability recorded upon issuance of convertible notes and warrants	`DerivativeLiabilityRecordedUponIssuanceOfConvertibleNotesAndAttachedWarrants`	-	USD	3 Qtrs
Derivative liability recorded upon issuance of convertible notes and warrants	`DerivativeLiabilityRecordedUponIssuanceOfConvertibleNotesAndAttachedWarrants`	$5.54M	USD	20 Qtrs
Derivative liability recorded as offering cost	`DerivativeLiabilityRecordedAsPrivatePlacementCost`	$642.30K	USD	3 Qtrs
Derivative liability recorded as offering cost	`DerivativeLiabilityRecordedAsPrivatePlacementCost`	$182.08K	USD	3 Qtrs
Derivative liability recorded as offering cost	`DerivativeLiabilityRecordedAsPrivatePlacementCost`	$824.38K	USD	20 Qtrs
Common stock issued for intellectual property	`StockIssued1`	$217.41K	USD	20 Qtrs
Common stock issued for intellectual property	`StockIssued1`	-	USD	3 Qtrs
Common stock issued for intellectual property	`StockIssued1`	-	USD	3 Qtrs
Proceeds from convertible notes held in escrow	`ProceedsFromConvertibleNotesHeldInEscrow`	-	USD	3 Qtrs
Proceeds from convertible notes held in escrow	`ProceedsFromConvertibleNotesHeldInEscrow`	-	USD	20 Qtrs
Proceeds from convertible notes held in escrow	`ProceedsFromConvertibleNotesHeldInEscrow`	$2.32M	USD	3 Qtrs
Forgiveness of debt by director, treated as contribution of capital	`DebtInstrumentDecreaseForgiveness`	-	USD	3 Qtrs
Forgiveness of debt by director, treated as contribution of capital	`DebtInstrumentDecreaseForgiveness`	$18.14K	USD	20 Qtrs
Forgiveness of debt by director, treated as contribution of capital	`DebtInstrumentDecreaseForgiveness`	-	USD	3 Qtrs

Stockholders Equity 13 line items

Line Item	Tag	Value	Unit	Period
Beginning Balance, Amount	`StockholdersEquity`	$-12.78M	USD	Point-in-time
Beginning Balance, Amount	`StockholdersEquity`	$-16.58M	USD	Point-in-time
Common stock sold in private placement at $1.00 per share, February 2012, Amount	`StockIssuedDuringPeriodValueNewIssues`	$67.92K	USD	3 Qtrs
Common stock issued to consultants for services, Amount	`StockIssuedDuringPeriodValueIssuedForServices`	$50.00K	USD	3 Qtrs
Fair value of common stock issued with notes payable	`DebtConversionOriginalDebtAmount1`	$497.89K	USD	3 Qtrs
Fair value of vested stock options	`ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodFairValue`	$2.36M	USD	3 Qtrs
Net loss	`NetIncomeLoss`	$-34.15M	USD	20 Qtrs
Net loss	`NetIncomeLoss`	$-673.90K	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-6.77M	USD	3 Qtrs
Net loss	`NetIncomeLoss`	$-5.82M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-17.34M	USD	3 Qtrs
Ending Balance, Amount	`StockholdersEquity`	$-12.78M	USD	Point-in-time
Ending Balance, Amount	`StockholdersEquity`	$-16.58M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.